Cognitive training for gynecologic cancer survivors experiencing cognitive impairment
A Pilot and Mixed-Methods Study of GYNecologic Cancer-Related COGnitive Impairment
NA · Northwestern University · NCT06662435
This study is testing a home-based brain training program to see if it can help women who have finished chemotherapy for gynecologic cancers and are having trouble with thinking and memory.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Northwestern University (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06662435 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate a home-based cognitive training intervention tailored for women who have completed chemotherapy for gynecologic cancers and are experiencing cancer-related cognitive impairment (CRCI). The intervention focuses on structured cognitive exercises designed to enhance cognitive function and mitigate the effects of CRCI, which affects a significant number of cancer survivors. Given the lack of established treatments for CRCI, this study seeks to empower patients and improve their quality of life through targeted cognitive training. Participants will be assessed for cognitive impairment and will engage in the cognitive training program remotely.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older who have completed chemotherapy for gynecologic cancers and report cognitive impairment.
Not a fit: Patients who have not undergone chemotherapy or have pre-existing neuropsychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve cognitive function and quality of life for gynecologic cancer survivors suffering from cognitive impairment.
How similar studies have performed: Existing literature suggests that cognitive training has shown promise in improving cognitive function in similar patient populations, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female; ≥18 years of age * Presents to clinic with a confirmed diagnosis of a gynecologic cancer (e.g., ovarian, endometrial, cervical, or vulvar cancer) who have completed adjuvant chemotherapy with at least stable disease at time of screening. * Screen positive for subjective cognitive impairment by answering affirmatively to at least one of three screener questions * Fluent in spoken and written English * Have access to the internet to complete assessments Exclusion Criteria: * Patients who have not received chemotherapy * Patients with pre-existing neuropsychiatric disorders that would impact cognitive function, such as dementia, Alzheimer's disease, and schizophrenia. * Patients with non-gynecologic causes of incurable metastatic cancers. * Patients undergoing active interventions in other cognitive trials or patients currently using cognitive training programs such as Brain HQ, Luminosity, Elevate, Peak, Fit Brains, or CogniFit. * Patients with self-report of learning disability or an unwillingness to participate in technology-based cognitive training programs. * Pregnant women or prisoners * Patients with impaired-decision making capacity
Where this trial is running
Chicago, Illinois
- Northwestern University — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Emma Barber, MD, MS — Northwestern University
- Study coordinator: Anne Grace, PhD
- Email: anne@northwestern.edu
- Phone: 312-503-4165
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer, cognitive impairment